Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$4.26 +2.0%	$5.58	$2.90 ▼ $11.16	$344.31M	0.47	3.36 million shs	432,998 shs
CMPX Compass Therapeutics	$3.11 +4.2%	$2.35	$0.87 ▼ $4.08	$423.83M	1.48	977,878 shs	78,652 shs
ETON Eton Pharmaceuticals	$14.57 +1.0%	$16.31	$3.25 ▼ $21.48	$388.73M	1.18	270,050 shs	24,021 shs
OPTN OptiNose	$9.60	$9.57	$4.82 ▼ $18.75	$97.22M	-0.88	63,472 shs	N/A

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	-1.88%	-8.73%	-39.60%	-5.00%	-47.09%
CMPX Compass Therapeutics	+2.05%	+12.45%	+23.65%	+75.29%	+195.05%
ETON Eton Pharmaceuticals	-0.76%	-8.67%	+0.91%	+2.49%	+332.04%
OPTN OptiNose	0.00%	0.00%	0.00%	+4.80%	-49.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALT Altimmune	2.1879 of 5 stars	3.4	1.0	0.0	3.2	1.7	0.6
CMPX Compass Therapeutics	3.0331 of 5 stars	3.6	1.0	0.0	3.4	5.0	0.0
ETON Eton Pharmaceuticals	2.0994 of 5 stars	3.5	1.0	0.0	2.5	1.7	0.6
OPTN OptiNose	0.6561 of 5 stars	1.0	0.0	4.2	0.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	2.75	Moderate Buy	$18.20	326.83% Upside
CMPX Compass Therapeutics	3.10	Buy	$12.67	307.94% Upside
ETON Eton Pharmaceuticals	3.00	Buy	$29.67	103.61% Upside
OPTN OptiNose	2.00	Hold	$9.00	-6.25% Downside

Current Analyst Ratings Breakdown

Latest OPTN, ETON, ALT, and CMPX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	ALT Altimmune	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
7/10/2025	ALT Altimmune	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$25.00 ➝ $15.00
7/1/2025	CMPX Compass Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform	$9.00
6/27/2025	ALT Altimmune	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
6/27/2025	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
5/29/2025	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $35.00
5/19/2025	OPTN OptiNose	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$9.00 ➝ $9.00
5/16/2025	ETON Eton Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $26.00
5/14/2025	ETON Eton Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$26.00 ➝ $28.00
5/9/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
4/28/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$20K	17,292.65	N/A	N/A	$1.74 per share	2.45
CMPX Compass Therapeutics	$850K	505.13	N/A	N/A	$0.91 per share	3.41
ETON Eton Pharmaceuticals	$48.33M	8.09	N/A	N/A	$0.94 per share	15.50
OPTN OptiNose	$81.86M	1.19	N/A	N/A	($11.56) per share	-0.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$95.06M	-$1.26	N/A	N/A	N/A	-451,200.00%	-65.44%	-58.43%	8/6/2025 (Estimated)
CMPX Compass Therapeutics	-$49.38M	-$0.41	N/A	N/A	N/A	N/A	-42.47%	-38.31%	8/11/2025 (Estimated)
ETON Eton Pharmaceuticals	-$3.82M	-$0.18	N/A	29.14	N/A	-9.49%	-3.15%	-1.08%	8/4/2025 (Estimated)
OPTN OptiNose	-$35.48M	-$3.00	N/A	N/A	N/A	-41.16%	N/A	-27.42%	8/6/2025 (Estimated)

Latest OPTN, ETON, ALT, and CMPX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	CMPX Compass Therapeutics	-$0.13	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	ALT Altimmune	-$0.3006	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	ALT Altimmune	-$0.35	-$0.26	+$0.09	-$0.26	$0.00 million	$0.01 million
5/13/2025	Q1 2025	ETON Eton Pharmaceuticals	$0.09	$0.07	-$0.02	-$0.06	$14.33 million	$17.28 million
5/13/2025	Q1 2025	OPTN OptiNose	-$0.74	-$1.01	-$0.27	-$1.92	$17.70 million	$18.51 million
5/8/2025	Q1 2025	CMPX Compass Therapeutics	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OPTN OptiNose	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	N/A	15.85	15.85
CMPX Compass Therapeutics	N/A	8.33	8.33
ETON Eton Pharmaceuticals	1.23	1.97	1.43
OPTN OptiNose	N/A	0.79	0.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
CMPX Compass Therapeutics	68.43%
ETON Eton Pharmaceuticals	27.86%
OPTN OptiNose	85.60%

Insider Ownership

Company	Insider Ownership
ALT Altimmune	4.10%
CMPX Compass Therapeutics	29.80%
ETON Eton Pharmaceuticals	14.89%
OPTN OptiNose	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	50	81.11 million	77.78 million	Optionable
CMPX Compass Therapeutics	20	138.28 million	97.08 million	Not Optionable
ETON Eton Pharmaceuticals	20	26.82 million	22.83 million	Optionable
OPTN OptiNose	190	10.13 million	9.83 million	Not Optionable

OPTN, ETON, ALT, and CMPX Headlines

Recent News About These Companies

Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies

May 21, 2025 | finance.yahoo.com

Optinose Stockholders Approve Merger with Paratek

May 16, 2025 | tipranks.com

OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates

May 14, 2025 | zacks.com

OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN

April 29, 2025 | businesswire.com

Optinose Reports 2024 Financial Results, Highlights Prescription Growth and First Operational Income

March 28, 2025 | msn.com

Optinose reports Q4 EPS (3c) vs ($1.33) last year

March 27, 2025 | markets.businessinsider.com

Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

March 26, 2025 | markets.businessinsider.com

OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates

March 26, 2025 | zacks.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GB, RDFN, PRA, OPTN on Behalf of Shareholders

March 25, 2025 | morningstar.comM

Wall Street Analysts Believe OptiNose (OPTN) Could Rally 143.06%: Here's is How to Trade

March 24, 2025 | zacks.com

Optinose downgraded to Neutral from Buy at H.C. Wainwright

March 22, 2025 | markets.businessinsider.com

OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN

March 21, 2025 | businesswire.com

OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek

March 21, 2025 | zacks.com

Optinose downgraded to Neutral from Overweight at Piper Sandler

March 21, 2025 | markets.businessinsider.com

Optinose downgraded to Hold from Buy at Lake Street

March 21, 2025 | markets.businessinsider.com

Why OptiNose Inc. (OPTN) Surged On Thursday?

March 21, 2025 | msn.com

Lake Street Downgrades OptiNose (OPTN)

March 21, 2025 | msn.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BECN and OPTN on Behalf of Shareholders

March 21, 2025 | globenewswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of OptiNose, Inc. - OPTN

March 20, 2025 | gurufocus.com

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of OptiNose, Inc. - OPTN

March 20, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
Do They Know Something? Insiders & Congress Buy UnitedHealth
By Brian O'Connell | July 9, 2025
View Do They Know Something? Insiders & Congress Buy UnitedHealth
Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
By Chris Markoch | July 6, 2025
View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
Top 3 Silver Picks to Watch as Bull Market Gains Steam
By Chris Markoch | June 18, 2025
View Top 3 Silver Picks to Watch as Bull Market Gains Steam
Why Realty Income’s 5.59% Yield Makes It a Must-Buy REIT
By Jeffrey Neal Johnson | July 2, 2025
View Why Realty Income’s 5.59% Yield Makes It a Must-Buy REIT

OPTN, ETON, ALT, and CMPX Company Descriptions

Altimmune NASDAQ:ALT

$4.26 +0.08 (+2.01%)

As of 10:21 AM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Compass Therapeutics NASDAQ:CMPX

$3.10 +0.13 (+4.19%)

As of 10:21 AM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Eton Pharmaceuticals NASDAQ:ETON

$14.57 +0.14 (+0.97%)

As of 10:21 AM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

OptiNose NASDAQ:OPTN

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time